cer-2021-0216_Supplemental Figure 3
- Statistical Analysis Plan
- Supplementary Figure 1. PRISMA flow chart of the systematic literature review.
- Supplementary Figure 2. Evidence networks in Type 1 and Types 2/3 SMA.
- Supplementary Figure 3. Histogram of re-scaled weights in the ENDEAR-matched FIREFISH population (total N=58).
- Supplementary Figure 4. Overall survival in patients with Type 1 SMA treated with nusinersen, risdiplam and BSC.
- Supplementary Figure 5. Histograms of re-scaled weights in the CHERISH-matched SUNFISH population.
- Supplementary Figure 6. Matching of SUNFISH and CHERISH placebo groups for RULM and HFMSE.
- Supplementary Table 1. PICOS framework and additional search criteria for the SLR.
- Supplementary Table 2. List of data sources used in the SLR.
- Supplementary Table 3. Key deviations from statistical analysis plan and justification.
- Supplementary Table 4. Clinical trials excluded from the SLR.
- Supplementary Table 5. Availability of endpoints of interest in Type 1 SMA.
- Supplementary Table 6. Baseline characteristics of FIREFISH pre- and post‑matching with STR1VE‑US (MAIC analysis).
- Supplementary Table 7. STC model fit statistics of FIREFISH versus STR1VE-US.
- Supplementary Table 8. BSID-III covariate estimates (STC FIREFISH vs STR1VE-US).
- Supplementary Table 9. CHOP-INTEND covariate estimates (STC FIREFISH vs STR1VE-US).
- Supplementary Table 10. Availability of endpoints of interest in Types 2 and 3 SMA.
- Supplementary Table 11. Analyses of HFMSE outcomes in SUNFISH and CHERISH at Month 12.
